Literature DB >> 23127611

Sequencing of t(2;7) translocations reveals a consistent breakpoint linking CDK6 to the IGK locus in indolent B-cell neoplasia.

Edward P K Parker1, Reiner Siebert, Thein H Oo, Douglas Schneider, Sandrine Hayette, Chen Wang.   

Abstract

The translocation t(2;7)(p11;q21) has repeatedly been documented in association with indolent B-cell lymphoproliferative disorders (BLPDs). However, the chromosomal breakpoints associated with this recurrent translocation have rarely been characterized. Using an approach based on long-range PCR, we mapped the t(2;7) breakpoints in five patients presenting with indolent B-cell neoplasia. The sequencing of these rearrangements revealed several striking parallels across the t(2;7) breakpoints. The junction sites on 2p11 consistently mapped to the heptamer recombination signal sequence (RSS) of an immunoglobulin kappa variable gene (IGK) within the Vκ3 family, while the breakpoints on 7q21 each localized to within 4 bp of an RSS-like element located approximately 0.5 kb upstream of the transcription start site of the cyclin-dependent kinase 6 gene (CDK6). These findings confirm the significant genetic overlap arising in BLPD-associated t(2;7) translocations, and implicate the deregulated expression of CDK6 as a common molecular mechanism involved in the emergence of clonal B-cell proliferations presenting with this recurrent abnormality. In addition, the successful mapping of the t(2;7) translocations in each of five patients using a simple PCR-based protocol highlights the potential diagnostic utility of this approach during characterization of cases harboring analogous rearrangements.
Copyright © 2013 American Society for Investigative Pathology and the Association for Molecular Pathology. Published by Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 23127611     DOI: 10.1016/j.jmoldx.2012.07.006

Source DB:  PubMed          Journal:  J Mol Diagn        ISSN: 1525-1578            Impact factor:   5.568


  5 in total

Review 1.  Targeting CDK6 in cancer: State of the art and new insights.

Authors:  Solomon Tadesse; Mingfeng Yu; Malika Kumarasiri; Bich Thuy Le; Shudong Wang
Journal:  Cell Cycle       Date:  2015       Impact factor: 4.534

2.  FusionPro, a Versatile Proteogenomic Tool for Identification of Novel Fusion Transcripts and Their Potential Translation Products in Cancer Cells.

Authors:  Chae-Yeon Kim; Keun Na; Saeram Park; Seul-Ki Jeong; Jin-Young Cho; Heon Shin; Min Jung Lee; Gyoonhee Han; Young-Ki Paik
Journal:  Mol Cell Proteomics       Date:  2019-06-17       Impact factor: 5.911

3.  Pathway Analysis of Genome-wide Association Study in Childhood Leukemia among Hispanics.

Authors:  Ling-I Hsu; Farren Briggs; Xiaorong Shao; Catherine Metayer; Joseph L Wiemels; Anand P Chokkalingam; Lisa F Barcellos
Journal:  Cancer Epidemiol Biomarkers Prev       Date:  2016-03-03       Impact factor: 4.254

4.  A kinase-independent function of CDK6 links the cell cycle to tumor angiogenesis.

Authors:  Karoline Kollmann; Gerwin Heller; Christine Schneckenleithner; Wolfgang Warsch; Ruth Scheicher; Rene G Ott; Markus Schäfer; Sabine Fajmann; Michaela Schlederer; Ana-Iris Schiefer; Ursula Reichart; Matthias Mayerhofer; Christoph Hoeller; Sabine Zöchbauer-Müller; Dontscho Kerjaschki; Christoph Bock; Lukas Kenner; Gerald Hoefler; Michael Freissmuth; Anthony R Green; Richard Moriggl; Meinrad Busslinger; Marcos Malumbres; Veronika Sexl
Journal:  Cancer Cell       Date:  2013-08-12       Impact factor: 31.743

Review 5.  Treating cancer with selective CDK4/6 inhibitors.

Authors:  Ben O'Leary; Richard S Finn; Nicholas C Turner
Journal:  Nat Rev Clin Oncol       Date:  2016-03-31       Impact factor: 66.675

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.